Article summary
As Australia becomes one of the first places to officially embrace (or at least tolerate) psychedelic assisted therapy (PAT), it’s worth asking: just how much psilocybin does the Australian therapeutic market need and what is the market potentially worth? How does this compare to the kind of money can be made from delivering PAT? The decisions of investors and activists alike will be heavily influenced by how these scenarios play out. For my best guesses on at least two of these questions, served with a side of irreverence, read on! (Disclaimer: Brace yourself for a journey filled with sarcasm, cynicism, satire, and plain-speaking. If any of these elements aren't your cup of tea, you might want to stick to more conventional reading options.)
Continue to the original publication for the complete article.